Happier Feet- A Smart Insole for Diabetic Foot Ulceration Prevention

NCT ID: NCT05865353

Last Updated: 2024-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-01

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to design, develop, and evaluate a smart insole to predict the formation of diabetic foot ulcers (DFUs) in diabetic participants at risk of developing them. The study will be conducted in two phases, using mixed-method research and engaging both diabetic participants and NHS clinicians. In Phase 1, the user-centred design of the smart insole will be developed through focus groups and online questionnaires, and a preliminary safety evaluation of the insole will be conducted with healthy team members. In Phase 2, the insole will be tested, validated, and data will be collected through baseline visits, lab studies, and insole data collection with shape-changed (pressure off-loading) insoles. The study will be conducted by researchers from the University of Manchester and the University of Exeter. It will include 10 people with diabetes and 10 healthy controls in Phase 2.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The tasks in this phase will be conducted by researchers from the University of Manchester and the University of Exeter. All tasks will be held at the University of Exeter.

Recruited participants will attend three sessions (tasks) on three non-consecutive days in the span of three months.

Participants will be identified either through participant identifying centres (e.g., Manchester diabetes clinic) or through direct contact from ad response. From these identified patients, lists will be screened by either general practitioners (for National Health Service (NHS) sites) or the University of Manchester and University o Exeter researchers (for direct contact) according to eligibility criteria. Eligible participants will be written to and invited to return a reply slip detailing whether they are interested in taking part. The return slips will contain all necessary details of the study, including participant information sheets. These must be given to eligible participants at least 48 hours before any planned interview sessions.

Eligible participants that return reply slips, or email the research team to say they are interested, will be contacted by phone by a researcher to clarify any questions they may have. The researcher will then notify the participant of the schedule for the sessions. On the arranged date, before the sessions, the participant will complete the consent process.

n = 20 (10 diabetic participants, 10 healthy similar controls)

1. Task 2.1 Baseline Visit: Eligibility confirmation and health screening session

* Consented participants will be asked to attend an eligibility confirmation, health evaluation and foot measurements session.
* This includes:

* Two-minute walk to evaluate the walking capability
* Gait and core kinematics evaluation (using IMU sensors and motion capture cameras)
* Physical Activity Readiness questionnaire (PAR-Q) to determine whether the participant is fit to carry out walking-related activities
* Monofilament test of the foot (for neuropathy) - Cutaneous pressure perception will be assessed using a 10 g monofilament at the first, third, and fifth prominent metatarsal heads on each foot, with the absence of sensation at any one site indicating neuropathy.
* Foot measurements and evaluation of anatomical landmarks using a High-Resolution pressure mat (HR-Mat, Tekscan).
* Participants will also have a fitting session for the co-developed pressure-relief smart insole. Participants will be asked to wear the insoles and give feedback on fitting.

Data Collection Method:

\- Qualitative data

Gait and core kinematics evaluation data will be collected in the form of electronic signals (from Intreial Measurement Unit (IMU) sensors) and videos (motion capture cameras)

Data collected during the baseline visit will be both qualitative and quantitative.
1. Qualitative data:

1. Qualitative data may be filled in by the participants at the beginning of the baseline visit or prior to the visit, provided the participants have been given the Participant Information Sheet (PIS) at least 48 hours prior to the visit.
2. Qualitative data collected within this task are:

i. Signed participant forms - (i) Decisional capacity evaluation, (ii) consent, (iii) inclusion/exclusion ii. Demographic data - age, sex, weight, iii. Physical Activity Readiness Questionnaire (PAR-Q) iv. Researcher notes v. Monofilament foot test for neuropathy - noted as yes/no for neuropathy.
2. Quantitative data:

a. Quantitative data collected within this task are: i. Gait and core kinematics evaluation: using Inertial Measurement Unit (IMU) sensors (physiobiometric) and motion capture cameras and Azure Kinect (data = video files collected and reviewed in the university-managed computer). This will be analysed using Statistical Package for the Social Sciences (SPSS) v.28 or onwards ii. Foot pressure readings (standing) will be collected via HR-Mat in the form of electronic signals that is collected via the HR-Mat Tekscan Research app in a university-managed laptop.
2. Task 2.2 Pilot laboratory - Insole data collection • The first study (Task 2.2) is a pilot evaluation in the lab to collect insole data for a series of activities. The activities are the same between the diabetic and control groups:

1. Participants will be asked to wear the smart insole while sitting (10 minutes), standing (5 minutes), and walking on a treadmill at a self-selected normal pace (15 minutes).
2. Participants will be asked to repeat the procedure after a 20 minutes rest.
3. After repeating the procedure, participants will rest for up to 15 minutes, after which participants will be asked to do a final short 2-5 minute walk on the ground.
4. Participants will be asked for feedback on the insole and their experience with the study.

\- Participants' health will be monitored throughout the study- heart rate, blood pressure, and blood glucose

Data Collection Method:

\- Quantitative data Insole data in the form of electronic signals will be collected via the electronic hub (of the insole) and sent via Bluetooth to a university-managed laptop. The data will be recorded and stored in secure folders on the university-managed laptop, followed by further analyses.

Participant health (heart rate, blood pressure and blood glucose)

\- Qualitative data Qualitative data collected will also be a short questionnaire on the feedback on the usability and acceptability of the insole.

Participant satisfaction, experience and feedback on the insole/study will be collected through a questionnaire that can either be answered via an electronic questionnaire or a physical copy.
3. Task 2.3 Lab study- insole data collection with shape-changed (pressure shape changed) insole

* The second study (Task 2.3) pilot evaluation in the lab to collect insole data for a series of activities with a bespoke shape-changed insole to offload the pressures of the foot. The procedures (study methods and data collection) will be as follows:

1. Participants will be asked to wear the smart insole while sitting (10 minutes), standing (5 minutes), and walking on a treadmill at a self-selected normal pace (15 minutes).
2. This is followed by a 20-minute rest. During which, a bespoke shape-changed insole will be fitted prior to the next activity.
3. Participants will repeat #1 with the bespoke shape-changed insole.
4. After repeating the procedure, participants will rest for up to 15 minutes, after which participants will be asked to do a final short 2-minute walk on the ground.
5. Participants will be asked for feedback on the insole and their experience with the study.
* Participants' health will be monitored throughout the study- heart rate, blood pressure, and blood glucose

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetes

Ten Diabetic participants at risk of DFU/ in this cross-sectional study, participants will be asked to use the smart insole and complete sitting, standing and walking task

No interventions assigned to this group

Healthy control

Ten healthy participants without movement disorder or Diabetes. The same tasks (sitting, standing and walking) while wearing the smart insole will be repeated for the control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Confirmed diagnosis of diabetes

1)At the risk of developing a DFU 2) Able to understand and communicate to safely participate \[Brief Assessment of Capacity 3) to have a score at least 6/8 (UBACC)\]Capacity to participate 4) capability to walk for 10 mins without rest 5) Be able to walk for 30 minutes with no pain, no walking aid, and take breaks if required.

6\) Must have sensation on their feet 7) Able to walk without a walking aid or orthotic.


1. Above 18 years old
2. Able to walk for 30 minutes with no pain, no walking aid, and taking breaks if required.
3. No contraindications to walking and physical activity
4. No broken skin on the foot
5. Do not suffer from a skin condition such as severe eczema or skin allergies.

Exclusion Criteria

1. Below 18 years old
2. Contradictions to walking and physical activity
3. Broken skin on the foot
4. Suffering from a skin condition such as severe eczema or skin allergies
5. Pain affecting the ability to walk.

Healthy participants


1. below 18 years old
2. Any movement disorder
3. Pain during the walk
4. Broken skin on the foot.
5. suffer from a skin condition such as severe eczema or skin allergies.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Manchester

OTHER

Sponsor Role collaborator

Loughborough University

OTHER

Sponsor Role collaborator

University of Southampton

OTHER

Sponsor Role collaborator

University of Strathclyde

OTHER

Sponsor Role collaborator

University of Exeter

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Helen Dawes, PhD

Role: PRINCIPAL_INVESTIGATOR

Professor of Clinical Rehabilitations

Andrew Weightman, PhD

Role: PRINCIPAL_INVESTIGATOR

Professor of Medical Mechatronics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Exeter

Exeter, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

307041

Identifier Type: OTHER

Identifier Source: secondary_id

2021-22-30

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Diabetic Foot Ulcer Prevention System
NCT02317835 COMPLETED PHASE1